Benzinga | Sep 22, 2020 07:11AM EDT

Guggenheim Downgrades CytomX Therapeutics to Neutral

Guggenheim analyst Etzer Darout downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Neutral.